Por recordar que Chugai ( Grupo Roche ) Abono 30 Millones como Pago Inicial por la Firma del contrato del PM1183 para Japón y hacían constar otros 70 Millones a abonar por Hitos a conseguir ( Total 100 Millones de euros ) .
***************************
May , 3 - 2017 . Edison Investment Lifts Valuation Off PharmaMar By 16% To €1.50 Bn ( Vs €1.29 Bn ), Or €6.75 / Share ( vs €5.79 / Share ) .
At its recent R&D day in New York, PharmaMar flagged endometrial cancer as a likely fourth indication for lurbinectedin (data to be presented at ASCO).
It confirmed that it is on track to achieve the key milestones of an approval decision for Aplidin for multiple myeloma in Europe, and Phase III results for lurbinectedin in ovarian cancer this year, with the most likely timing in Q4.
The company emphasised its goal of commercialising lurbinectedin itself in the US market, prompting us to adopt self-commercialisation as our base case valuation scenario, which lifts our valuation by 16% to €1.50bn (vs €1.29bn), or €6.75/share (vs €5.79/share).